Inhibitor of fatty acid synthase (FAS) reducing food intake and body weight in mice. Exhibits irreversible slow-binding biphasic inactivation of fatty acid synthase. Downregulates neuropeptide Y and Agouti-related protein expression. Has been proposed to activate CPT-1 activity in liver and adipose tissue, leading to increased fatty acid oxidation and energy production. Shows significant in vivo antitumor activity in human breast cancer cells. Suppresses DNA replication and induces apoptosis. FAS inhibition by C75 leads to a dramatic accumulation of the CDK inhibitor p27KIP1 from cytosol to cell nuclei.
Product Details
| Alternative Name: | trans-4-Carboxy-5-octyl-3-methylene-butyrolactone |
| |
| Formula: | C14H22O4 |
| |
| MW: | 254.3 |
| |
| Source: | Synthetic. |
| |
| CAS: | 191282-48-1 |
| |
| Purity: | ≥98% |
| |
| Appearance: | White to off-white solid. |
| |
| Solubility: | Soluble in dichloromethane, methanol or DMSO. |
| |
| Shipping: | Ambient |
| |
| Long Term Storage: | -20°C |
| |
| Handling: | Protect from light. |
| |
| Regulatory Status: | RUO - Research Use Only |
| |
Please mouse over
Product Literature References
Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells: J.A. Menendez, et al.; Oncogenesis
6, e299 (2017),
Abstract;
Full Text
To complete its replication cycle, a shrimp virus changes the population of long chain fatty acids during infection via the PI3K-Akt-mTOR-HIF1α pathway: Y.C. Hsieh, et al.; Dev. Comp. Immunol.
53, 85 (2015),
Application(s): Injection into shrimp,
Abstract;
C75 activates malonyl-CoA sensitive and insensitive components of the CPT system: C. Nicot, et al.; BBRC
325, 660 (2004),
Abstract;
C75, a fatty acid synthase inhibitor, modulates AMP-activated protein kinase to alter neuronal energy metabolism: L.E. Landree, et al.; J. Biol. Chem.
279, 3817 (2004),
Abstract;
Inhibition of tumor-associated fatty acid synthase activity antagonizes estradiol- and tamoxifen-induced agonist transactivation of estrogen receptor (ER) in human endometrial adenocarcinoma cells: J.A. Menendez, et al.; Oncogene
23, 4945 (2004),
Abstract;
Long-term effects of a fatty acid synthase inhibitor on obese mice: food intake, hypothalamic neuropeptides, and UCP3: S.H. Cha, et al.; BBRC
317, 301 (2004),
Abstract;
The anorexigenic fatty acid synthase inhibitor, C75, is a non-specific neuronal activator: K.A. Takahashi, et al.; Endocrinology
145, 184 (2004),
Abstract;
C75 inhibits food intake by increasing CNS glucose metabolism: M.D. Wortman, et al.; Nat. Med.
9, 483 (2003),
Abstract;
Effect of the anorectic fatty acid synthase inhibitor C75 on neuronal activity in the hypothalamus and brainstem: S. Gao & M.D. Lane; PNAS
100, 10 (2003),
Abstract;
Fatty Acid Synthase Inhibition Triggers Apoptosis during S Phase in Human Cancer Cells: W. Zhou, et al.; Cancer Res.
63, 7330 (2003),
Abstract;
Hypothalamic malonyl-CoA as a mediator of feeding behavior: Z. Hu, et al.; PNAS
100, 12624 (2003),
Abstract;
C75 increases peripheral energy utilization and fatty acid oxidation in diet-induced obesity: J.N. Thupari, et al.; PNAS
99, 9498 (2002),
Abstract;
Comparison of central and peripheral administration of c75 on food intake, body weight, and conditioned taste aversion: D.J. Clegg, et al.; Diabetes
51, 3196 (2002),
Abstract;
Differential effects of a centrally acting fatty acid synthase inhibitor in lean and obese mice: M.V. Kumar, et al.; PNAS
99, 1921 (2002),
Abstract;
Full Text
Effect of a fatty acid synthase inhibitor on food intake and expression of hypothalamic neuropeptides: T. Shimokawa, et al.; PNAS
99, 66 (2002),
Abstract;
Expression of FAS within hypothalamic neurons: a model for decreased food intake after C75 treatment: E.K. Kim, et al.; Am. J. Physiol. Endocrinol. Metab.
283, E867 (2002),
Abstract;
Green tea epigallocatechin gallate: a natural inhibitor of fatty-acid synthase: X. Wang & W. Tian; BBRC
288, 1200 (2001),
Abstract;
Increased fatty acid synthase is a therapeutic target in mesothelioma: E.W. Gabrielson, et al.; Clin. Cancer Res.
7, 153 (2001),
Abstract;
Pharmacological inhibition of fatty acid synthase activity produces both cytostatic and cytotoxic effects modulated by p53: J.N. Li, et al.; Cancer Res.
61, 1493 (2001),
Abstract;
Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts: E.S. Pizer, et al.; Cancer Res.
60, 213 (2000),
Abstract;
Reduced food intake and body weight in mice treated with fatty acid synthase inhibitors: T.M. Loftus, et al.; Science
288, 2379 (2000),
Abstract;
Synthesis and antitumor activity of an inhibitor of fatty acid synthase: F.P. Kuhajda, et al.; PNAS
97, 3450 (2000),
Abstract;
Pharmacological inhibitors of mammalian fatty acid synthase suppress DNA replication and induce apoptosis in tumor cell lines: E.S. Pizer, et al.; Cancer Res.
58, 4611 (1998),
Abstract;
